EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Update on Management of Ductal Carcinoma in Situ

Joanna T Buchheit, David Schacht, Swati A Kulkarni

Clinical Breast Cancer · 2024-06 · 24 (4) · 292-300

DOI: 10.1016/j.clbc.2023.12.010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Breast Cancer, 2024-06. Verfasst von Joanna T Buchheit und 2 weiteren Autor:innen. Beteiligte Einrichtung: Northwestern Quality Improvement, Research, & Education in Surgery (NQUIRES), Northwestern University Feinberg School of Medicine, Chicago, IL. Hauptthemen laut MEDLINE: Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 94 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ductal carcinoma in situ (DCIS) represents 18% to 25% of all diagnosed breast cancers, and is a noninvasive, nonobligate precursor lesion to invasive cancer. The diagnosis of DCIS represents a wide range of disease, including lesions with both low and high risk of progression to invasive cancer and recurrence. Over the past decade, research on the topic of DCIS has focused on the possibility of tailoring treatment for patients according to their risk for progression and recurrence, which is based on clinicopathologic, biomolecular and genetic factors. These efforts are ongoing, with recently completed and continuing clinical trials spanning the continuum of cancer care. We conducted a review to identify recent advances on the topic of diagnosis, risk stratification and management of DCIS. While novel imaging techniques have increased the rate of DCIS diagnosis, questions persist regarding the optimal management of lesions that would not be identified with conventional methods. Additionally, among trials investigating the potential for omission of surgery and use of active surveillance, 2 trials have completed accrual and 2 clinical trials are continuing to enroll patients. Identification of novel genetic patterns is expanding our potential for risk stratification and aiding our ability to de-escalate radiation and systemic therapies for DCIS. These advances provide hope for tailoring of DCIS treatment in the near future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCarcinoma, Intraductal, NoninfiltratingHumansFemaleNeoplasm Recurrence, LocalDisease Progression

Stichwörter der Autor:innen

De-escalationDuctal carcinoma in situEndocrine therapyOmission of surgeryRisk stratification

Autor:innen und Institutionen

  • Northwestern Quality Improvement, Research, & Education in Surgery (NQUIRES), Northwestern University Feinberg School of Medicine, Chicago, IL.
  • Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL.
  • Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL. Electronic address…

Zitieren

APA

Buchheit, J. T., Schacht, D., & Kulkarni, S. A. (2024). Update on Management of Ductal Carcinoma in Situ. Clinical Breast Cancer, 24(4), 292-300. https://doi.org/10.1016/j.clbc.2023.12.010

Vancouver

Buchheit JT, Schacht D, Kulkarni SA. Update on Management of Ductal Carcinoma in Situ. Clinical Breast Cancer. 2024;24(4):292-300. doi:10.1016/j.clbc.2023.12.010

BibTeX
@article{Buchheit2024,
  author = {Buchheit, Joanna T and Schacht, David and Kulkarni, Swati A},
  title = {Update on Management of Ductal Carcinoma in Situ},
  journal = {Clinical Breast Cancer},
  year = {2024},
  volume = {24},
  number = {4},
  pages = {292--300},
  doi = {10.1016/j.clbc.2023.12.010}
}
Kostenlos starten →